methyl 5-[4-(3-chloro-4-methoxybenzylamino)-6-chlorothieno[2,3-d]-pyrimidin-2-yl]valerate | 1098997-08-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: methyl 5-[4-(3-chloro-4-methoxybenzylamino)-6-chlorothieno[2,3-d]-pyrimidin-2-yl]valerate
• 英文别名: Methyl 5-[6-chloro-4-[(3-chloro-4-methoxyphenyl)methylamino]thieno[2,3-d]pyrimidin-2-yl]pentanoate
• CAS: 1098997-08-0
• 化学式: C₂₀H₂₁Cl₂N₃O₃S
• 分子量: 454.377
• InChiKey: YXOBTAGVFGPXJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
  申请人：——

  公开号：US20040077664A1

  公开（公告）日：2004-04-22

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor and at least one nitrate for the preparation of a medicament for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency and liver cirrhosis.

  含有至少一种磷酸二酯酶V抑制剂和至少一种硝酸盐的药物制剂，用于制备治疗心绞痛、高血压、肺动脉高压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心衰竭、动脉粥样硬化、心血管通路通畅度降低、外周血管疾病、中风、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾功能不全和肝硬化的药物。
• Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
  申请人：——

  公开号：US20040072846A1

  公开（公告）日：2004-04-15

  The invention relates to a pharmaceutical preparation containing at least one compound of formula (I) wherein R 1 , R 2 , R 3 , R 4 , n and X have the same meaning as cited in claim 1, and the physiologically acceptable salts thereof and/or solvates and a) at least one antithrombotic or b) at least one calcium antagonist or c) at least one prostaglandin or prostaglandin derivative for producing a medicament for treating angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chromic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, astheriosclerosis, conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, cirrhosis of the liver and for treating female sexual problems. 1

  本发明涉及一种药物制剂，其含有至少一种式（I）化合物，其中R1、R2、R3、R4、n和X的含义与权利要求1中所述相同，并且其生理上可接受的盐和/或溶剂，以及a）至少一种抗血栓剂，或b）至少一种钙拮抗剂，或c）至少一种前列腺素或前列腺素衍生物，用于制备治疗心绞痛、高血压、肺动脉高压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心室衰竭、动脉粥样硬化、心血管通路减少症、周围血管疾病、脑卒中、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合症、肿瘤、肾功能衰竭、肝硬化和治疗女性性问题的药物。
• Use of thienopyrimidines
  申请人：——

  公开号：US20040034040A1

  公开（公告）日：2004-02-19

  The invention relates to the use of thienopyrimidines of formula (I)—wherein R 1 , R 2 , R 3 , R 4 and X have the designations cited in claim 1—and the physiologically acceptable salts thereof, for producing a medicament for the treatment of angina, hypertension, pulmonary hypertension, congestive heart failure, arteriosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, and cirrhosis of the liver, and for the treatment of female sexual disorders.

  本发明涉及使用式(I)中的噻吩嘧啶，其中R1、R2、R3、R4和X具有权利要求书中所述的标识，以及其生理上可接受的盐，用于生产治疗心绞痛、高血压、肺动脉高压、充血性心力衰竭、动脉硬化、心血管血管通透性降低、周围血管疾病、中风、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾衰竭和肝硬化，以及治疗女性性功能障碍的药物。
• Thienopyrimidines
  申请人：Merck Patent GmbH

  公开号：US20020132818A1

  公开（公告）日：2002-09-19

  The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.

  公式（I）的噻唑嘧啶及其生理兼容盐显示出磷酸二酯酶V抑制活性，可用于治疗心血管系统疾病以及治疗和/或治疗勃起功能障碍。
• Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
  申请人：——

  公开号：US20040063731A1

  公开（公告）日：2004-04-01

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.

  含有至少一种磷酸二酯酶V抑制剂，和/或其生理上可接受的盐和/或溶剂，以及至少一种内皮素受体拮抗剂的制药制剂，用于制备治疗心绞痛、高血压、高肺动脉压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心衰竭、动脉粥样硬化、心血管疾病血管通透性降低、周围血管疾病、中风、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾功能不全、肝硬化、勃起功能障碍和治疗女性性功能障碍的药物。